Health & Fitness
Wed, May 23, 2012
WHITEHOUSE STATION, N.J.--([ BUSINESS WIRE ])--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Alex Kelly, senior vice president, investor relations, is scheduled to present at the Bank of America Merrill Lynch 2012 Healthcare Conference in Las Vegas, on May 17 at 11:40 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at: [ http://www.merck.com/investors/events-and-presentations/home.html ].
About Merck
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit [ www.merck.com ] and connect with us on Twitter, Facebook and YouTube.
Forward-Looking Statement
This news release includes aforward-looking statementsa within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined companyas plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merckas management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merckas ability to accurately predict future market conditions; dependence on the effectiveness of Merckas patents and other protections for innovative products; and the exposure to litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merckas 2011 Annual Report on Form 10-K and the companyas other filings with the Securities and Exchange Commission (SEC) available at the SECas Internet site ([ www.sec.gov ]).